Leap Therapeutics reported that while the study showed some activity in biomarker populations, it failed to produce a decisive positive signal. The study's data suggested a high level of ...

H.C. Wainwright downgraded Leap Therapeutics (LPTX) to Neutral from Buy without a price target after the company presented clinical data updates from two ongoing Phase 2 studies, DeFianCe and ...

Shares of Leap Therapeutics slid after disappointing initial data from two mid-stage clinical trials of its oncology treatment, resulting in the discontinuation of one clinical program.

Jan. 28, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data ...

Leap Therapeutics, Inc.'s DKN-01 showed disappointing results in the DisTinGuish trial for gastric and gastroesophageal junction cancer. The DeFianCe trial in colorectal cancer was closer to ...

Leap Therapeutics stock opened at $0.52 on Wednesday. Leap Therapeutics has a one year low of $0.51 and a one year high of $4.79. The company has a 50-day simple moving average of $2.78 and a 200 ...